TRCT
CGTX icon

Tower Research Capital (TRC)’s Cognition Therapeutics CGTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,339
Closed -$4.05K – 5255
2026
Q1 		$4.05K Buy
+5,339
New +$6.21K ﹤0.01% 4232
2025
Q4 		– Sell
-1,996
Closed -$2.69K – 5196
2025
Q3 		$2.69K Buy
+1,996
New +$2.72K ﹤0.01% 4597
2025
Q2 		– Sell
-2,444
Closed -$1.03K – 5285
2025
Q1 		$1.03K Sell
2,444
-18,526
-88% -$10.9K ﹤0.01% 4782
2024
Q4 		$14.7K Buy
20,970
+9,980
+91% +$4.93K ﹤0.01% 3450
2024
Q3 		$5.15K Buy
10,990
+359
+3% +$370 ﹤0.01% 4320
2024
Q2 		$17.6K Buy
10,631
+4,213
+66% +$8.4K ﹤0.01% 3827
2024
Q1 		$11.7K Buy
6,418
+1,551
+32% +$3.2K ﹤0.01% 3542
2023
Q4 		$9K Buy
4,867
+1,308
+37% +$1.73K ﹤0.01% 4448
2023
Q3 		$5.13K Sell
3,559
-703
-16% -$1.1K ﹤0.01% 4757
2023
Q2 		$7.8K Sell
4,262
-1,063
-20% -$2.25K ﹤0.01% 4524
2023
Q1 		$11K Buy
5,325
+1,131
+27% +$2.15K ﹤0.01% 4190
2022
Q4 		$9K Buy
4,194
+3,257
+348% +$6.58K ﹤0.01% 4171
2022
Q3 		$2K Sell
937
-970
-51% -$2.02K ﹤0.01% 5531
2022
Q2 		$4K Buy
+1,907
New +$4.93K ﹤0.01% 5178

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Tower Research Capital (TRC)'s CGTX Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Cognition Therapeutics (CGTX) in Q2 2026, closing a stake of 5,339 shares — an estimated $4.05K sold.

Tower Research Capital (TRC) first reported a position in CGTX in Q2 2022 and held it in 14 quarters. The position peaked at $17.6K in Q2 2024. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining Cognition Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 5,339 Cognition Therapeutics shares in Q2 2026, an estimated $4.05K.
  • Tower Research Capital (TRC) first reported a position in Cognition Therapeutics in Q2 2022 and held it in 14 quarters.
  • Tower Research Capital (TRC)'s Cognition Therapeutics position peaked at $17.6K in Q2 2024.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.